Evidence map›Paper›PMID 33253155›Full record

ArticlePloS one2020

Chemical profiling and anti-psoriatic activity of marine sponge (Dysidea avara) in induced imiquimod-psoriasis-skin model.

Mostafa Khaledi, Behzad Sharif Makhmal Zadeh, Annahita Rezaie, Melika Nazemi, Mehdi Safdarian, Mohammad Bagher Nabavi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mostafa KhalediMarine Pharmaceutical Science Research Center, Department of Pharmacognosy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID 0000-0001-7891-2243
Behzad Sharif Makhmal ZadehNanotechnology Research Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID 0000-0002-1441-3127
Annahita RezaieDepartment of Pathobiology Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
Melika NazemiGulf and Oman Sea Ecological Research Center, Iranian Fisheries Science Research Institute (IFSRI), Agricultural Research, Education and Extension Organization (AREEO), Bandar Abbas, Iran.
Mehdi SafdarianNanotechnology Research Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID 0000-0001-9735-2632
Mohammad Bagher NabaviHalal Research Center of Islamic Republic of Iran, Tehran, Iran.
Ahvaz Jundishapur University of Medical Sciences · IRAgricultural Research & Education Organization · IRShahid Chamran University of Ahvaz · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since Marine sponge Dysidea avara is regarded as a source of anti-inflammatory compounds, we decided to evaluate its potential anti-psoriatic activity in a psoriasis Imiquimod-induced in the mouse model. Psoriatic mice were treated with three different methanolic extracts of Dysidea avara compared with betamethasone-treated mice in in- vivo studies. Clinical skin severity was assessed with the psoriasis area index (PASI), whilst ELISA detected the expression of TNF-α, IL-17A, and IL-22. Dysidea avara activity was studied by employing GC-MS (to distinguish compounds), HPTLC (for skin permeation and accumulation), and SEA DOCK to predict single compound potential anti-inflammatory activity. After 7 days of treatment, mice treated with Dysidea avara displayed a dose-dependent, statistically significant improvement compared to controls (p< 0.001). In line with the clinical results, ELISA revealed a statistically significant decrease in IL-22, IL-17A, and TNF-α after treatment; the same SEA DOCK analysis suggests a possible anti-psoriatic activity of the extracts.

Indexed as

DysideaAnimalsAnti-Inflammatory AgentsBiological ProductsDisease Models, AnimalDrug Evaluation, PreclinicalFemaleHumansImiquimodInterleukin-17Interleukin-22InterleukinsMicePsoriasisSeverity of Illness IndexSkinAnti-Inflammatory AgentsBiological ProductsIl17a protein, mouseImiquimodInterleukin-17Interleukin-22InterleukinsTnf protein, mouseTumor Necrosis Factor-alpha

Identifiers

PMID33253155
PMCPMC7703918
OpenAlexW3109853605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.